CanSinoBIO rejects low efficacy of its vaccine against covid-19

The CanSinoBIO r companythrew low efficacy of its vaccine against covid. On the contrary, he said that “it is greater than 90 percent to prevent serious pictures and 65 percent to avoid contagion.”

Regarding the diffusion of the low effectiveness CanSinoBIO expressed that “each one of the vaccines produced in China has independent technology, manufacturing and scientific studies, so it is an error to use the term“ Chinese vaccines ”to refer to companies with solutions. different biopharmaceuticals.

“We reiterate that the CanSinoBIO anticovid vaccine Ad5-nCoV or Convidecia, which is applied in a single dose, has an efficacy of 90% to avoid serious cases of covid-19, and 65% to avoid contracting the disease. This is a percentage higher than the minimum required by the World Health Organization (WHO), which is 50% “

At a press conference, the company stated that “the development process of the covid-19 vaccines It is open to each and every pharmaceutical company.

“None of the vaccines that are currently being applied in the world have completed their phase 3 studies, since by international regulations these studies must last from 18 to 24 months.

“As this is a process in full development, it is very possible that each and every one of the vaccines that we currently know will have to make adjustments in the number of doses, vaccination schedules or reconfiguration of their formula, due to issues such as variants of virus or the immune response in some regions “

And he assured that “CanSinoBIO is a Chinese biopharmaceutical company with more than 12 years of experience that is committed to helping Mexico achieve the goal of mass immunization with an effective, safe and easy-to-use vaccine, which means the life, health and well-being of millions of people ”.​

​KACY

–
– .